Eli Lilly and Company $LLY Shares Sold by William Blair Investment Management LLC

William Blair Investment Management LLC cut its stake in Eli Lilly and Company (NYSE:LLY) by 3.5% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,288 shares of the company’s stock after selling 769 shares during the period. William Blair Investment Management LLC’s holdings in Eli Lilly and Company were worth $24,632,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of LLY. PFC Capital Group Inc. grew its position in Eli Lilly and Company by 1.3% during the 3rd quarter. PFC Capital Group Inc. now owns 6,256 shares of the company’s stock worth $7,239,000 after purchasing an additional 83 shares during the last quarter. Money Concepts Capital Corp increased its stake in Eli Lilly and Company by 2.7% during the 3rd quarter. Money Concepts Capital Corp now owns 14,218 shares of the company’s stock valued at $16,452,000 after purchasing an additional 377 shares in the last quarter. GKV Capital Management Co. Inc. increased its stake in Eli Lilly and Company by 0.3% during the 3rd quarter. GKV Capital Management Co. Inc. now owns 13,969 shares of the company’s stock valued at $16,163,000 after purchasing an additional 43 shares in the last quarter. Fisher Asset Management LLC raised its holdings in shares of Eli Lilly and Company by 7.1% in the third quarter. Fisher Asset Management LLC now owns 5,424,027 shares of the company’s stock worth $6,276,034,000 after buying an additional 360,511 shares during the last quarter. Finally, Legacy Trust raised its holdings in shares of Eli Lilly and Company by 59.6% in the third quarter. Legacy Trust now owns 3,841 shares of the company’s stock worth $4,444,000 after buying an additional 1,435 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the transaction, the executive vice president directly owned 4,137 shares in the company, valued at approximately $5,802,225.24. The trade was a 54.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by insiders.

Key Headlines Impacting Eli Lilly and Company

Investors following LLY have been watching these headlines:

• Positive Sentiment: China approved Lilly’s oral weight-loss drug orforglipron, marketed as Foundayo. As the first GLP-1 weight-loss pill approved in China, it gives Lilly an early foothold in a large market and could broaden access beyond injectable treatments; competition from other drugmakers remains a factor. Reuters: China approves Eli Lilly’s weight loss pill orforglipron
• Positive Sentiment: Hims & Hers will offer Lilly’s FDA-approved Zepbound and Foundayo, potentially extending patient reach through another care platform. Separately, exchange-traded funds were reported to have added to their Lilly holdings, signaling investor demand. Hims partners with Lilly to offer weight-loss drugs
• Neutral Sentiment: Lilly is advancing an early-stage ALS drug study, but investors are still waiting for clinical data, so the update does not yet establish whether the treatment will succeed. Eli Lilly advances early ALS drug study

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock traded up $16.77 during midday trading on Friday, hitting $1,444.05. 2,080,606 shares of the company were exchanged, compared to its average volume of 3,003,279. The firm has a market capitalization of $1.36 trillion, a PE ratio of 46.87, a price-to-earnings-growth ratio of 1.71 and a beta of 0.40. Eli Lilly and Company has a fifty-two week low of $850.51 and a fifty-two week high of $1,460.00. The business has a fifty day simple moving average of $1,242.25 and a two-hundred day simple moving average of $1,110.30. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The firm had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. During the same period in the previous year, the firm earned $7.02 EPS. The business’s quarterly revenue was up 38.6% on a year-over-year basis. On average, sell-side analysts forecast that Eli Lilly and Company will post 35.70 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is presently 22.46%.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on LLY. Bank of America reiterated a “buy” rating and set a $1,497.00 price objective on shares of Eli Lilly and Company in a research note on Friday, October 30th. Truist Financial reissued a “buy” rating and issued a $1,612.00 target price (up from $1,376.00) on shares of Eli Lilly and Company in a research report on Friday, October 30th. Wall Street Zen raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. Argus raised their target price on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Finally, Wells Fargo & Company lifted their price target on Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $1,416.64.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.